04770nam 2200721 a 450 991096687010332120251017110109.09786612644870978030915648603091564839781282644878128264487497803091502550309150256(CKB)2670000000040023(EBL)3378620(SSID)ssj0000426426(PQKBManifestationID)11261967(PQKBTitleCode)TC0000426426(PQKBWorkID)10373035(PQKB)11063276(Au-PeEL)EBL3378620(CaPaEBR)ebr10395834(CaONFJC)MIL264487(OCoLC)923281822(MiAaPQ)EBC3378620(Perlego)4736342(DNLM)1537597(EXLCZ)99267000000004002320100803d2010 uy 0engurcn|||||||||txtccrThe Public Health Emergency Medical Countermeasures Enterprise innovative strategies to enhance products from discovery through approval : workshop summary /Theresa Wizemann, Clare Stroud and Bruce M. Altevogt ; Forum on Medical and Public Health Preparedness for Catastrophic Events, Forum on Drug Discovery, Development and Translation, Board on Health Sciences Policy1st ed.Washington, D.C. National Academies Press20101 online resource (194 p.)The national academiesDescription based upon print version of record.9780309150248 0309150248 Includes bibliographical references.""Front Matter""; ""Reviewers""; ""Contents""; ""INTRODUCTION""; ""BACKGROUND""; ""PARTNERS IN A SINGLE MISSION, DIVERSE CONCERNS AND CHALLENGES""; ""EXAMPLES OF SUCCESSFUL COUNTERMEASURES DEVELOPMENT AND DEPLOYMENT""; ""PARTNERSHIPS AND ALTERNATIVE BUSINESS MODELS""; ""ENGAGING INDUSTRY""; ""NEW PARADIGMS, STRATEGIES, AND TACTICS FOR ENHANCING THE COUNTERMEASURES DEVELOPMENT ENTERPRISE""; ""EXISTING REGULATORY TOOLS AND APPROACHES THAT CAN BE APPLIED TO ADVANCE COUNTERMEASURES DEVELOPMENT""; ""CONCLUSION""; ""Appendix A: References""; ""Appendix B: Workshop Agenda""""Appendix C: Registered Workshop Attendees""""Appendix D: Case Studies of HHS Chemical, Biological, Radiological, and Nuclear Medical Countermeasure Development Programs, Executive Summary""; ""Appendix E: Synthesis of Business Models and Economic and Market Incentives for Vaccines and Therapeutics"""During public health emergencies such as pandemic influenza outbreaks or terrorist attacks, effective vaccines, drugs, diagnostics, and other medical countermeasures are essential to protecting national security and the public's well-being. The Public Health Emergency Medical Countermeasures Enterprise (PHEMCE--a partnership among federal, state, and local governments; industry; and academia) is at the forefront of the effort to develop and manufacture these countermeasures. However, despite the PHEMCE's many successes, there are still serious challenges to overcome. Government-funded medical research is not always focused on countermeasures for the most serious potential threats, and it is difficult to engage pharmaceutical and biotechnology companies to develop and manufacture medical countermeasures that have a limited commercial market. At the request of the Secretary of the U.S. Department of Health and Human Services and the Assistant Secretary for Preparedness and Response, the IOM held a workshop February 22-24, 2010, to address challenges facing the PHEMCE. Workshop participants discussed federal policies and procedures affecting the research, development, and approval of medical countermeasures and explored opportunities to improve the process and protect Americans' safety and health"--National Academies Press description.Emergency medicineCongressesEmergency medicine362.1Wizemann Theresa M890630Stroud Clare1601279Altevogt Bruce M1791694Institute of Medicine (U.S.).Forum on Medical and Public Health Preparedness for Catastrophic Events.Institute of Medicine (U.S.).Forum on Drug Discovery, Development, and Translation.Institute of Medicine (U.S.).Board on Health Sciences Policy.MiAaPQMiAaPQMiAaPQBOOK9910966870103321The Public Health Emergency Medical Countermeasures Enterprise4355018UNINA